ZSAN · Zosano Pharma Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $785.0K | $224.0K | $0 | $0 | $0 | $0 |
| Cost of Revenue | $796.0K | $171.0K | - | - | - | - |
| Gross Profit | ($11.0K) | $53.0K | - | - | - | - |
| R&D | $20.97M | $21.62M | $25.39M | $25.51M | $20.19M | $20.46M |
| SG&A | $10.55M | $11.19M | $11.81M | $9.36M | $8.18M | $8.18M |
| Total Operating Expenses | $32.32M | $32.98M | $37.20M | $35.38M | $28.37M | $28.63M |
| D&A | $1.75M | $1.40M | $700.0K | $800.0K | $2.55M | $2.54M |
| Operating Income | ($31.53M) | ($32.76M) | ($37.20M) | ($35.38M) | ($28.37M) | ($28.63M) |
| Interest Expense | $189.0K | $719.0K | $523.0K | $817.0K | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($29.93M) | ($33.37M) | ($37.59M) | ($35.36M) | ($29.11M) | ($29.83M) |
| EPS - Basic | ($0.49) | - | - | - | - | - |
| EPS - Diluted | ($0.49) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.04M | $35.26M | $6.32M | $9.14M | $11.65M | $15.00M |
| Accounts Receivable | $0 | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.12M | $1.88M | $4.36M | $4.45M | $1.51M | $1.45M |
| Current Assets | $11.61M | $35.72M | $6.81M | $23.36M | $13.39M | $15.28M |
| Total Assets | $48.39M | $72.01M | $37.67M | $35.78M | $18.00M | $20.91M |
| Current Liabilities | $11.13M | $14.51M | $16.24M | $11.29M | $10.46M | $9.82M |
| Long-term Debt | $0 | $812.0K | - | - | $6.69M | $12.54M |
| Total Liabilities | $15.41M | $24.50M | $28.28M | $17.07M | $10.95M | $16.42M |
| Stockholders' Equity | $32.98M | $47.52M | $9.39M | $18.71M | $7.05M | $4.49M |
| Retained Earnings | ($362.12M) | ($332.19M) | ($298.82M) | ($261.23M) | ($225.87M) | ($196.77M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($27.59M) | ($31.72M) | ($29.12M) | ($29.12M) | ($27.12M) | ($25.69M) |
| Investing Cash Flow | ($5.42M) | ($8.49M) | ($19.21M) | ($19.21M) | ($1.23M) | $30.27M |
| Financing Cash Flow | $8.79M | $69.15M | $45.82M | $45.82M | $25.00M | $3.77M |
| CapEx | $5.42M | $8.49M | $11.76M | $5.49M | $1.24M | $287.0K |
| Free Cash Flow | ($33.01M) | ($40.20M) | ($40.88M) | ($34.61M) | ($28.36M) | ($25.97M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | -1.4% | 23.7% | - | - | - | - |
| Operating margin | -4016.8% | -14624.1% | - | - | - | - |
| EBITDA margin | -3793.8% | -13999.1% | - | - | - | - |
| Net margin | -3812.1% | -14896.9% | - | - | - | - |
| Free cash flow margin | -4205.5% | -17948.7% | - | - | - | - |
| FCF / Net income | 1.10 | 1.20 | 1.09 | 0.98 | 0.97 | 0.87 |
| R&D / Revenue | 2671.8% | 9652.7% | - | - | - | - |
| SG&A / Revenue | 1343.6% | 4995.1% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -61.8% | -46.3% | -99.8% | -98.8% | -161.7% | -142.7% |
| Return on equity | -90.8% | -70.2% | -400.2% | -189.0% | -413.0% | -665.2% |
| Return on invested capital | -75.5% | -53.5% | - | - | -163.2% | -132.8% |
| Liquidity | ||||||
| Current ratio | 1.04 | 2.46 | 0.42 | 2.07 | 1.28 | 1.56 |
| Quick ratio | 1.04 | 2.46 | 0.42 | 2.07 | 1.28 | 1.56 |
| Cash ratio | 0.99 | 2.43 | 0.39 | 0.81 | 1.11 | 1.53 |
| Leverage | ||||||
| Debt / Equity | 0.00 | 0.02 | - | - | 0.95 | 2.80 |
| Debt / Assets | 0.00 | 0.01 | - | - | 0.37 | 0.60 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -166.8x | -45.6x | -71.1x | -43.3x | - | - |
| Equity multiplier | 1.47 | 1.52 | 4.01 | 1.91 | 2.55 | 4.66 |
| Liabilities / Assets | 0.32 | 0.34 | 0.75 | 0.48 | 0.61 | 0.79 |
| Efficiency | ||||||
| Asset turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 0d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 972d | 4021d | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 250.4% | - | - | - | - | -100.0% |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | -39.9% | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 3.7% | 11.9% | -5.1% | -24.7% | 0.9% | -127.0% |
| Net income growth (YoY) | 10.3% | 11.2% | -6.3% | -21.5% | 2.4% | -109.5% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 17.9% | 1.7% | -18.1% | -22.0% | -9.2% | -114.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -30.6% | 405.9% | -49.8% | 165.5% | 57.1% | 840.3% |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-7.44
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Zosano Pharma Corp against the 5 most active filers in the same SIC group.